Salvage surgery for advanced renal cell carcinoma

European Urology, Supplements

Volumn 3, Issue 3, 2004, Pages 2-8

  Mickisch, Gerald H ^a  

^a Center of Operative Urology Bremen   (Germany)

Author keywords

Advanced disease; Immunotherapy; Lymphadenectomy; Randomized trials; Renal cancer; Tumor nephrectomy

Indexed keywords

ADVANCED CANCER; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; EVIDENCE BASED MEDICINE; EXPERIMENTAL THERAPY; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MEDLINE; METASTASECTOMY; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT OUTCOME;

EID: 1542286221     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2004.02.002     Document Type: Conference Paper

References (28)

1. Mickisch G.H.J. Principles of nephrectomy for malignant disease. BJU Int. 89:2002;488-495.
2. Mickisch G.H.J. Surgical approaches to organ-confined renal cell carcinoma. Onkologie. 23:2000;208-212.
3. Mickisch G.H., Carballido J., Hellsten S., Schulze H., Mensink H. Guidelines on renal cancer. Eur. Urol. 40:2001;252-255.
4. Mickisch G.H.J. Lymph node dissection for renal cell carcinoma - the value of operation and adjuvant therapy. Urologe (A). 38:1999;326-331.
5. Blom J.H.M., van Poppel H., Marechal J.M., Jacqmin P., Sylvester R., Schröder F.H., et al. members of the EORTC-GU group Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomised phase III protocol 30881. Eur. Urol. 36:1999;570-575.
6. Bukowsky R.M. Natural history and therapy of metastatic renal cell carcinoma. Cancer. 80:1997;1198-1220.
7. De Riese W., Goldenberg K., Allhoff E. Metastatic renal cell carcinoma: Spontaneous regression. long-term survival and late recurrence. Int. Urol. Nephrol. 23:1991;13-25.
8. Mickisch G.H.J. Rational selection of a control arm for randomized trials in metastatic renal cell carcinoma. Eur. Urol. 43:2003;670-679.
9. van Brussel J., Mickisch G.H. Prognostic factors in renal cell and bladder cancer. Br. J. Urol. 83:1999;902-909.
10. Kavolius J.P., Mastorakos D.P., Pavlovich C. Resection of metastatic renal cell carcinoma. J. Clin. Oncol. 16:1998;2261-2266.
11. Noordzij MA, Mickisch GHJ. The genetic make up of renal tumors. Urol Res, in press.
12. Walther M.M., Yang J.C., Pass H.l. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J. Urol. 158:1997;1675-1678.
13. Tigrani V.S., Reese D.M., Small E.J., Presti J.C. Jr., Carroll P.R. Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: a retrospective analysis. Urology. 55:2000;36-40.
14. Bennett R.T., Lerner S.E., Taub H.C. Cytoreductive surgery for stage IV renal cell carcinoma. J. Urol. 154:1995;32-34.
15. Taneja S.S., Pierce W., Figlin R. Immunotherapy for renal cell carcinoma: the era of interleukin-2 based treatment. Urology. 45:1995;911-914.
16. Fallick M.L., McDermott D.F., LaRock D. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J. Urol. 158:1997;1691-1695.
17. Mickisch G.H., Garin A., van Poppel H., de Prijck L., Sylvester R. Radical nephrectomy plus Interferon-alpha based immunotherapy compared with interferon-alpha alone in metastatic renal cell carcinoma: a randomized trial. Lancet. 358:2001;966-970.
18. Flanigan R.C., Salmon S., Blumenstein B.A., Bearman S.I., Roy V., McGrath P.C., et al. Nephrectomy followed by interferon alpha-2b compared with interferon alpha-2b alone for metastatic renal cell cancer. New Engl. J. Med. 345:2001;1655-1659.
19. Walther M.M., Lyne J.C., Libutti S.K., Linehan W.M. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study. Urology. 53:1999;496-501.
20. Fleischmann J.D., Kim B. Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J. Urol. 145:1991;938-941.
21. Wagner J.R., Walther M.M., Linehan W.M., White D.E., Rosenberg S.A. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J. Urol. 162:1999;43-45.
22. Rackley R., Novick A.C., Klein E.A. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J. Urol. 152:1994;1399-1403.
23. Krishnamurthi V., Novick A.C., Bukowski R.M. Efficacy of multimodality therapy in advanced renal cell carcinoma. Urology. 51:1998;933-937.
24. Negrier S., Escudier B., Lasset C., Douillard J.Y., Savary J., Chevreau C., et al. Recombinant human interleukin-2, recombinant human interferon alpha-2a, or both in metastatic renal cell carcinoma. New Engl. J. Med. 338:2000;1272-1278.
25. Atzpodien J., Kirchner H., Illiger H.J., Metzner B., Ukena D., Schott H., et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br. J. Cancer. 85:2001;1130-1136.
26. Vis AN, Gaast vdA, Rhijn vBWG, Catsburg TK, Schmidt C, Mickisch GHJ. A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy. Cancer Chemother Pharmacol 2002;49:342-5.
27. Motzer R.J., Mazumdar M., Bacik J., Russo P., Berg W.J., Metz E.M. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J. Clin. Oncol. 18:2000;1928-1935.
28. Medical Research Council Renal Cancer Collaborators. Interferon-α and survival in metastatic renal cell carcinoma: early results of a randomised controlled trial. Lancet 1999;353:301-5.